🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 therapy in patients over 65 — safety and efficacy data Page 5

GLP-1 therapy in patients over 65 — safety and efficacy data

GraceAZ_72 Sun, Apr 5, 2026 at 11:59 AM 40 replies 1,293 viewsPage 5 of 8
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Apr 10, 2026 at 8:40 PM#21
Dr.RaviCardio said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

I am going to disagree with the direction of travel here. The thread has converged on the tidiest answer rather than the best-supported one, and those are not the same thing.

18 16steve_okc, dave_SLC, FDA_TrackerJim and 15 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Apr 12, 2026 at 12:09 AM#22
Dr.RaviCardio said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

Last edited: Apr 12, 2026 at 5:09 AM
19 17traveltech_sara, AttorneyGrant, DebRD_ATL and 16 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Apr 13, 2026 at 3:38 AM#23
Dr.RaviCardio said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Genuinely useful, thank you. I had the facts and not the framework.

20 18gary_naperville, sean_dublin, hannah_MT and 17 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Apr 14, 2026 at 7:08 AM#24

Clinical perspective, offered as context rather than as advice. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

21 19AussieAnna, BethLabQueen, ChrisMacros and 18 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Apr 15, 2026 at 10:39 AM#25
sophie_paris said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

22 20MounjBrad, nick_newbie, DadBodDave and 19 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register